stockrowAbivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Return on assets
Abivax SA Sponsored ADR's return on assets over the twelve months to 30 June 2026 was −137.7%, down 51.6 percentage points from fiscal 2025 (−86.1%). Over the past ten years it has ranged from −86.1% (fiscal 2025) to 0.00% (fiscal 2018) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −86.1% | (19.90) |
| FY2024 | −66.2% | 7.55 |
| FY2023 | −73.8% | (11.36) |
| FY2022 | −62.4% | (16.45) |
| FY2021 | −46.0% | 12.97 |
| FY2020 | −58.9% | (1.70) |
| FY2019 | −57.2% | (57.22) |
| FY2018 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | 17.2% |
| ORKA Oruka Therapeutics, Inc. compare | −17.8% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −18.3% |
| AXSM Axsome Therapeutics, Inc. compare | −21.0% |
| SYRE Spyre Therapeutics, Inc. compare | −30.9% |
| PRAX Praxis Precision Medicines, Inc. compare | −36.8% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −41.8% |
| CYTK Cytokinetics, Incorporated compare | −47.7% |
| ABVX Abivax SA Sponsored ADR | −137.7% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)